drugset

drugset / Trial / NCT05210517

SGLT2 Inhibition: Uric Acid Excretion Study

NCT05210517 ↗

Phase 4 Completed 10 enrolled Amsterdam UMC, location VUmc

RandomizedCrossoverOpen-labelTreatment

Summary

The current study investigates the effects of SGLT2 inhibitor empagliflozin on uric acid excretion.

Timeline

Start: 2020-10-01
Primary completion: 2021-06-08
Completion: 2021-09-01

Publications

Suijk DLS, van Baar MJB, van Bommel EJM, Iqbal Z, Krebber MM, Vallon V, Touw D, Hoorn EJ, Nieuwdorp M, Kramer MMH, Joles JA, Bjornstad P, van Raalte DH. SGLT2 Inhibition and Uric Acid Excretion in Patients with Type 2 Diabetes and Normal Kidney Function. Clin J Am Soc Nephrol. 2022 May;17(5):663-671. doi: 10.2215/CJN.11480821. Epub 2022 Mar 23.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Benzbromarone	Small molecule	100 mg	—
Subject	Empagliflozin	Small molecule	25 mg	—

Indications